| Hazard Information | Back Directory | [in vivo]
Mitonafide (0.5 and 1 mg/kg, i.p., 1-7 days) shows antitumoral potency in S-180 bearing mice[4].
Mitonafide (5 mg/kg, i.p., twice a day) shows anticancer activity in HepG2 xenograft model[6].
Mitonafide (single i.p. injection, S-180 bearing mice) shows the LD50 value of 10.0 mg/kg[5].
| Animal Model: | S-180 bearing mice[4] | | Dosage: | 0.5 mg/kg and 1 mg/kg | | Administration: | Intraperitoneal injection (i.p.) for 1-7 days | | Result: | Increased in median survival times. |
| Animal Model: | HepG2 xenograft model [6] | | Dosage: | 5 mg/kg | | Administration: | Intraperitoneal injection (i.p.), twice a day. | | Result: | Exhibited a relative tumor increment rates (T/C) value of 28.8%. |
| [storage]
Store at -20°C |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
| Company Name: |
Synchem OHG
|
| Tel: |
+49 5662 408730 |
| Website: |
www.synchem.de |
|